Income Statement Balance Sheet Cash Flow Statement
Annual Financials for ImmunoCellular Therapeutics Ltd.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 300,000 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 3,397 3,633 20,357 45,823 50,402
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 3,397 3,633 20,357 45,823 50,402
Depreciation 3,397 3,633 20,357 45,823 50,402
Amortization of Intangibles - - - 0 0
Gross Income 296,603 (3,633) (20,357) (45,823) (50,402)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 2.94M 5.13M 8.61M 11.78M 9.41M
Research & Development 962,526 2.29M 4.99M 7.71M 5.34M
Other SG&A 1.98M 2.84M 3.62M 4.07M 4.07M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 1.02M (2.9M) 2.28M (642,411)
EBIT after Unusual Expense 0 (1.02M) 2.9M (2.28M) 642,411
Non Operating Income/Expense 0 0 0 (397,294) 0
Non-Operating Interest Income 22,045 4,105 4,346 8,609 17,345
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 0 0 0 0 0
Gross Interest Expense 0 0 0 0 0
Interest Capitalized 0 0 0 0 0
Pretax Income (2.63M) (6.15M) (5.72M) (14.5M) (8.8M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 - 0 0 0
Consolidated Net Income (2.63M) (6.15M) (5.72M) (14.5M) (8.8M)
Minority Interest Expense 0 0 0 0 0
Net Income (2.63M) (6.15M) (5.72M) (14.5M) (8.8M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (2.63M) (6.15M) (5.72M) (14.5M) (8.8M)
Preferred Dividends 0 2.09M 0 0 0
Net Income Available to Common (2.63M) (8.24M) (5.72M) (14.5M) (8.8M)
EPS (Basic) (0.19) (0.43) (0.21) (0.35) (0.16)
Basic Shares Outstanding 13.72M 19.19M 27.45M 41.8M 54.28M
EPS (Diluted) (0.19) (0.43) (0.21) (0.35) (0.16)
Diluted Shares Outstanding 13.72M 19.19M 27.45M 41.8M 54.28M
EBITDA (2.64M) (5.13M) (8.61M) (11.78M) (9.41M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.